Applied dna announces publication of peer-reviewed journal article validating potential use of lineardna™ as a new class of dna-based vaccines

Stony brook, n.y.--( business wire )--applied dna sciences, inc. (nasdaq: apdn) (the “company”), a leader in pcr-based dna technologies, today announced the publication of a peer-reviewed research article in molecular therapy – methods & clinical development. the study, titled ‘a linear dna vaccine candidate encoding the sars-cov-2 receptor binding domain elicits protective immunity in domestic cats,' supports the further development of the company's lineardna™ platform for the large-scale enzymatic (pcr, polymerase chain reaction) production of prophylactic and therapeutic lineardna™-based vaccines. an initial manuscript detailing the study's findings was published in preprint form on biorxiv in july 2022.
APDN Ratings Summary
APDN Quant Ranking